JAK inhibitor ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	5
50	Dermatomyositis	1

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05451615 (ClinicalTrials.gov)	September 30, 2022	17/6/2022	Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis	Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Rec ...	Abatacept;Treatment Compliance;Rheumatoid Arthritis	Drug: Janus Kinase Inhibitor;Drug: Abatacept	Zhejiang Provincial People's Hospital	NULL	Recruiting	N/A	N/A	All	90	Phase 3	China
2	NCT05379322 (ClinicalTrials.gov)	July 2022	12/5/2022	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Pati ...	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Pati ...	Rheumatoid Arthritis	Drug: Anti-TNF;Drug: JAK inhibitor	Abu Dhabi Stem Cells Center	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	United Arab Emirates
3	ChiCTR2100048699	2021-05-25	2021-07-12	A multicentre, randomized, parallel-controlled clinical study of the efficacy and safety of Iguratim ...	Clinical cohort study of organ injury and repair in severe rheumatic diseases---rheumatoid arthritis ...	Rheumatoid Arthritis	A:Iguratimod combination therapy with JAK inhibitor;B:JAK inhibitor;	Qilu Hospital of Shandong University	NULL	Recruiting	18	65	Both	A:180;B:180;		China
4	NCT05090410 (ClinicalTrials.gov)	March 3, 2021	30/9/2021	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ...	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ...	Rheumatoid Arthritis;JAK Inhibitor;IL-6 Inhibitor;Musculoskeletal Ultrasound;Biomarker	Drug: filgotinib 200mg/day;Drug: subcutaneous tocilizumab 162mg/biweekly	Atsushi Kawakami	Gilead Sciences	Recruiting	20 Years	N/A	All	400	Phase 3	Japan
5	NCT04378621 (ClinicalTrials.gov)	October 1, 2020	8/4/2020	Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-pati ...	Treatment of Inflammation Versus Hand Training to Prevent and Revert Neuropsychiatric Comorbidity in ...	Rheumatoid Arthritis;Pain;Fatigue;Cognitive Decline;Depression;Brain Diseases;Hand Rheumatism	Drug: TNF-a inhibitor OR JAK inhibitor;Other: Hand training	Vastra Gotaland Region	NULL	Active, not recruiting	45 Years	75 Years	All	212	N/A	Sweden

First Previous1Next Last

50. Dermatomyositis

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04966884 (ClinicalTrials.gov)	April 2, 2020	15/7/2021	The Efficacy and Safety of JAK Inhibitorin the Treatment of Anti-MDA5 Antibody-positive Dermatomyosi ...	The Efficacy and Safety of JAK Inhibitorin the Treatment of Anti-MDA5 Antibody-positive Dermatomyosi ...	Dermatomyositis, Adult Type	Drug: JAK Inhibitor	First Affiliated Hospital Xi'an Jiaotong University	NULL	Recruiting	18 Years	70 Years	All	20	Phase 4	China

First Previous1Next Last